Abstract
We previously reported the production of a panel of murine monoclonal antibodies which recognize glycoproteins abnormally expressed in human breast tumours. Using two of these antibodies, a double antibody radioimmunoassay was designed to quantify levels of these breast tumour marker glycoproteins in serum. Marker levels greater than 28 units were considered abnormal. Using this criterion, 63% and 75% of patients with breast cancer stages I and II, respectively, and 88% of those with metastatic disease were found to have elevated marker levels. Thirteen percent of patients with non-malignant breast disease also had elevated marker levels. Elevated marker levels were also detected in patients with non breast neoplasms. One hundred and eleven women with metastatic disease were followed. Eighty-two percent of those with progressive disease and 73% of those where disease regressed had 20% changes in marker levels. These changes in marker levels preceded by up to 6 months changes in disease state. From these results we conclude that this assay may be useful for monitoring the course of disease in breast cancer patients.
Highlights
Sera from patients with benign breast disease and primary breast cancer who had no clinical evidence of metastases were obtained prior to surgery
Linearity The standard curve generated with MB5 antigen is linear up to 90U
Standard curves were generated with quintuplicate values at each point on 6 different days; Figure 1 illustrates these results
Summary
Blood samples were allowed to clot and were centrifuged for 15 min at 800 g. The serum fraction was collected and 0.02% sodium azide was added to prevent. Received 28 October 1987; and in revised form, 17 March 1988. Normal sera were collected from apparently healthy women. Sera from patients with benign breast disease and primary breast cancer who had no clinical evidence of metastases were obtained prior to surgery.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
